[{"from": "human", "value": "Provide a description of this molecule. [C][C][Branch1][C][C][Branch1][=Branch1][C][=Branch1][C][=O][O][O][/N][=C][Branch1][O][/C][=C][S][C][=Branch1][Ring2][=N][Ring1][Branch1][N][\\C][=Branch1][C][=O][N][C@H1][C@@H1][N][Branch1][Branch1][C][Ring1][Ring2][=O][C][=Branch1][P][=C][Branch1][Branch1][C][S][Ring1][Branch2][C][N+1][=C][C][=C][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][O-1]"}, {"from": "gpt", "value": "The molecule is synthesized and remodelled through the action of a family of enzymes known as \"penicillin-binding proteins\" (PBPs). \u03b2-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.  Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-\u03b2-lactam \u03b2-lactamase inhibitor [avibactam] to treat a variety of bacterial infections."}]